Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 160-166

  Moreau Marquis, Sophie ^a   Coutermarsh, Bonita ^a   Stanton, Bruce A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Mucoviscidosis; OSCN ^{< sup>; P. aeruginosa}

Indexed keywords

AZTREONAM; BACTERICIDE; HYPOTHIOCYANITE; LACTOFERRIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DRUG COMBINATION; HYPOTHIOCYANITE ION; THIOCYANIC ACID DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOFILM; COCULTURE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG FIBROSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; SPUTUM; BACTERIAL COUNT; CELL CULTURE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; EPITHELIUM CELL; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; AZTREONAM; BIOFILMS; CELLS, CULTURED; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; DRUG SYNERGISM; EPITHELIAL CELLS; HUMANS; LACTOFERRIN; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; THIOCYANATES; TOBRAMYCIN;

EID: 84928315351     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku357     Document Type: Article

References (45)

1. Riordan J, Rommens J, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
2. Kerem B, Rommens J, Buchanan J et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
3. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cystic Fibrosis 2005; 4: 3-5.
4. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: doi:10.1186/741-7015-9-32.
5. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New Engl J Med 1996; 335: 179-88.
6. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194-222.
7. Singh PK, Schaefer AL, Parsek MR et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
8. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109: 317-25.
9. Moreau-Marquis S, Bomberger JM, Anderson GG et al. The DF508-CFTR mutation results in increased biofilm formation by P. aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L25-37.
10. Yu Q, Griffin EF, Moreau-Marquis S et al. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 2012; 67: 2673-81.
11. Stites S, Walters B, O'Brien-Ladner A et al. Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis. Chest 1998; 114: 814-9.
12. Stites SW, Plautz MW, Bailey K et al. Increased concentrations of iron and isoferritins in the lower respiratory tract of patients with stable cystic fibrosis. Am J Respir Crit Care Med 1999; 160: 796-801.
13. Alexis N, Richards J, Carter JD et al. Iron-binding and storage proteins in sputum. Inhal Toxicol 2002; 14: 387-400.
14. Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 2009; 41: 305-13.
15. Rogan MP, Taggart CC, Greene CM et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004; 190: 1245-53.
16. Moskwa P, Lorentzen D, Excoffon KJDA et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 174-83.
17. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002; 109: 693-7.
18. Singh P. Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 2004; 17: 267-70.
19. Drago-Serrano ME, de la Garza-Amaya M, Luna JS et al. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol 2012; 12: 1-9.
20. Farnaud S, Spiller C, Moriarty L et al. Interactions of lactoferricinderived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett 2004; 233: 193-209.
21. Britigan BE, Hayek MB, Doebbeling BN et al. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun 1993; 61: 5049-55.
22. Conner GE, Salathe M, Forteza R. Lactoperoxidase and hydrogen peroxide metabolism in the airway. Am J Respir Crit Care Med 2002; 166: S57-61.
23. El-Chemaly S, Salathe M, Baier S et al. Hydrogen peroxide-scavenging properties of normal human airway secretions. Am J Respir Crit Care Med 2003; 167: 425-30.
24. Thomas E. Lactoperoxidase-catalyzed oxidation of thiocyanate: equilibria between oxidized forms of thiocyanate. Biochemistry 1981; 20: 3273-80.
25. Thomas EL, Aune TM. Lactoperoxidase, peroxide, thiocyanate antimicrobial system: correlation of sulfhydryl oxidation with antimicrobial action. Infect Immun 1978; 20: 456-63.
26. Aune T, Thomas E. Oxidation of protein sulfhydryls by products of peroxidase-catalyzed oxidation of thiocyanate ion. Biochemistry 1978; 17: 1005-10.
27. Fragoso MA, Fernandez V, Forteza R et al. Transcellular thiocyanate transport by human airway epithelia. J Physiol 2004; 561: 183-94.
28. Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R et al. Lactoperoxidase and human airway host defense. Am J Respir Cell Mol Biol 2003; 29: 206-12.
29. Xu Y, Szep S, Lu Z. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc Natl Acad Sci USA 2009; 106: 20515-9.
30. Van der Vliet A, Nguyen MN, Shigenaga MK et al. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2000; 279: L537-46.
31. Dias C, Aires A, Bennett R et al. First study on antimicrobial activity and synergy between isothiocyanates and antibiotics against selected Gram-negative and Gram-positive pathogenic bacteria from clinical and animal source. Med Chem 2012; 8: 474-80.
32. Geller DE, Pitlick WH, Nardella PA et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-26.
33. FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting. Aztreonam for Inhalation Solution (NDA 50-814) for Improvement of Respiratory Symptoms in Cystic Fibrosis Patients. http://wwwfdagov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM193023pdf.
34. Bruscia E, Sangiuolo F, Sinibaldi P et al. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 2002; 9: 683-5.
35. Cozens A, Yezzi M, Kunzelmann K et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10: 38-47.
36. Anderson GG, Moreau-Marquis S, Stanton BA et al. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosisderived airway epithelial cells. Infect Immun 2008; 76: 1423-33.
37. Moreau-Marquis S, Redelman C, Stanton B et al. Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. J Vis Exp 2010; 44: 2186.
38. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-32.
39. Guntupalli K, Dean N, Morris P et al. A phase 2 randomized, doubleblind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41: 706-16.
40. Hancock REW, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resistance Updates 2000; 3: 247-55.
41. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
42. Hoffman LR, D'Argenio DA, MacCoss MJ et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-5.
43. Cohn RC, Jacobs M, Aronoff SC. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1988; 32: 395-6.
44. Cohn R, Rudzienski L, Putnam R. Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro. Chemotherapy 1995; 41: 330-3.
45. Treerat P, Widmer F, Middleton PG et al. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. FEMS Microbiol Lett 2008; 285: 40-50.